Cargando…
Diagnostic value of anti-topoisomerase I antibodies in a large monocentric cohort
INTRODUCTION: In the present study, the detection of anti-topoisomerase I (anti-topo I) autoantibodies was evaluated for diagnosis and risk assessment of systemic sclerosis (SSc) patients in a well characterized large monocentric cohort. METHODS: Sera from patients with SSc (diffuse n = 96, limited...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2688262/ https://www.ncbi.nlm.nih.gov/pubmed/19232127 http://dx.doi.org/10.1186/ar2622 |
_version_ | 1782167688346337280 |
---|---|
author | Hanke, Katharina Dähnrich, Cornelia Brückner, Claudia S Huscher, Dörte Becker, Mike Jansen, Anthonina Meyer, Wolfgang Egerer, Karl Hiepe, Falk Burmester, Gerd R Schlumberger, Wolfgang Riemekasten, Gabriela |
author_facet | Hanke, Katharina Dähnrich, Cornelia Brückner, Claudia S Huscher, Dörte Becker, Mike Jansen, Anthonina Meyer, Wolfgang Egerer, Karl Hiepe, Falk Burmester, Gerd R Schlumberger, Wolfgang Riemekasten, Gabriela |
author_sort | Hanke, Katharina |
collection | PubMed |
description | INTRODUCTION: In the present study, the detection of anti-topoisomerase I (anti-topo I) autoantibodies was evaluated for diagnosis and risk assessment of systemic sclerosis (SSc) patients in a well characterized large monocentric cohort. METHODS: Sera from patients with SSc (diffuse n = 96, limited n = 113), from patients with overlap syndromes (n = 51), from patients with other diseases associated with SSc (n = 20), as well as from disease controls (n = 487) were analysed for the presence of anti-topo I antibodies by line immunoblot assay and ELISA. Assessment of organ manifestations was performed as proposed by the European Scleroderma Trial and Research network. RESULTS: The applied test systems for the detection of anti-topo I antibodies revealed a diagnostic sensitivity for SSc of approximately 24% and a diagnostic specificity of at least 99.6%. The sensitivity to identify patients with diffuse SSc amounted to 60%. Patients with anti-topo I antibodies showed a higher burden of skin and lung fibrosis, contractures, electrocardiogram changes, as well as digital ulcers and had more active disease than antibody-negative patients. Signal strengths correlated only weakly with disease activity, with modified Rodnan skin score, with predicted forced vital capacity, and with predicted diffusion capacity levels (P = 0.01, ρ = 0.234, ρ = 0.413, ρ = -0.215, ρ = -0.219). High signal intensities were associated with an increased mortality in diffuse SSc patients (P = 0.003). CONCLUSIONS: Diagnosis and risk assessment of SSc patients can be supported by the detection of anti-topo I antibodies. Signal intensities as obtained by line immunoblot assay or ELISA can be used as a surrogate marker for fibrosis, active disease and worse prognosis. |
format | Text |
id | pubmed-2688262 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2009 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-26882622009-05-29 Diagnostic value of anti-topoisomerase I antibodies in a large monocentric cohort Hanke, Katharina Dähnrich, Cornelia Brückner, Claudia S Huscher, Dörte Becker, Mike Jansen, Anthonina Meyer, Wolfgang Egerer, Karl Hiepe, Falk Burmester, Gerd R Schlumberger, Wolfgang Riemekasten, Gabriela Arthritis Res Ther Research Article INTRODUCTION: In the present study, the detection of anti-topoisomerase I (anti-topo I) autoantibodies was evaluated for diagnosis and risk assessment of systemic sclerosis (SSc) patients in a well characterized large monocentric cohort. METHODS: Sera from patients with SSc (diffuse n = 96, limited n = 113), from patients with overlap syndromes (n = 51), from patients with other diseases associated with SSc (n = 20), as well as from disease controls (n = 487) were analysed for the presence of anti-topo I antibodies by line immunoblot assay and ELISA. Assessment of organ manifestations was performed as proposed by the European Scleroderma Trial and Research network. RESULTS: The applied test systems for the detection of anti-topo I antibodies revealed a diagnostic sensitivity for SSc of approximately 24% and a diagnostic specificity of at least 99.6%. The sensitivity to identify patients with diffuse SSc amounted to 60%. Patients with anti-topo I antibodies showed a higher burden of skin and lung fibrosis, contractures, electrocardiogram changes, as well as digital ulcers and had more active disease than antibody-negative patients. Signal strengths correlated only weakly with disease activity, with modified Rodnan skin score, with predicted forced vital capacity, and with predicted diffusion capacity levels (P = 0.01, ρ = 0.234, ρ = 0.413, ρ = -0.215, ρ = -0.219). High signal intensities were associated with an increased mortality in diffuse SSc patients (P = 0.003). CONCLUSIONS: Diagnosis and risk assessment of SSc patients can be supported by the detection of anti-topo I antibodies. Signal intensities as obtained by line immunoblot assay or ELISA can be used as a surrogate marker for fibrosis, active disease and worse prognosis. BioMed Central 2009 2009-02-21 /pmc/articles/PMC2688262/ /pubmed/19232127 http://dx.doi.org/10.1186/ar2622 Text en Copyright © 2009 Hanke et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an open access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Hanke, Katharina Dähnrich, Cornelia Brückner, Claudia S Huscher, Dörte Becker, Mike Jansen, Anthonina Meyer, Wolfgang Egerer, Karl Hiepe, Falk Burmester, Gerd R Schlumberger, Wolfgang Riemekasten, Gabriela Diagnostic value of anti-topoisomerase I antibodies in a large monocentric cohort |
title | Diagnostic value of anti-topoisomerase I antibodies in a large monocentric cohort |
title_full | Diagnostic value of anti-topoisomerase I antibodies in a large monocentric cohort |
title_fullStr | Diagnostic value of anti-topoisomerase I antibodies in a large monocentric cohort |
title_full_unstemmed | Diagnostic value of anti-topoisomerase I antibodies in a large monocentric cohort |
title_short | Diagnostic value of anti-topoisomerase I antibodies in a large monocentric cohort |
title_sort | diagnostic value of anti-topoisomerase i antibodies in a large monocentric cohort |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2688262/ https://www.ncbi.nlm.nih.gov/pubmed/19232127 http://dx.doi.org/10.1186/ar2622 |
work_keys_str_mv | AT hankekatharina diagnosticvalueofantitopoisomeraseiantibodiesinalargemonocentriccohort AT dahnrichcornelia diagnosticvalueofantitopoisomeraseiantibodiesinalargemonocentriccohort AT brucknerclaudias diagnosticvalueofantitopoisomeraseiantibodiesinalargemonocentriccohort AT huscherdorte diagnosticvalueofantitopoisomeraseiantibodiesinalargemonocentriccohort AT beckermike diagnosticvalueofantitopoisomeraseiantibodiesinalargemonocentriccohort AT jansenanthonina diagnosticvalueofantitopoisomeraseiantibodiesinalargemonocentriccohort AT meyerwolfgang diagnosticvalueofantitopoisomeraseiantibodiesinalargemonocentriccohort AT egererkarl diagnosticvalueofantitopoisomeraseiantibodiesinalargemonocentriccohort AT hiepefalk diagnosticvalueofantitopoisomeraseiantibodiesinalargemonocentriccohort AT burmestergerdr diagnosticvalueofantitopoisomeraseiantibodiesinalargemonocentriccohort AT schlumbergerwolfgang diagnosticvalueofantitopoisomeraseiantibodiesinalargemonocentriccohort AT riemekastengabriela diagnosticvalueofantitopoisomeraseiantibodiesinalargemonocentriccohort |